Table 1. Daiichi Sankyo's cardiovascular and endocrine/metabolic disease pipelines. The therapies that Daiichi Sankyo Co. Ltd. (Tokyo:4568) has in its pipelines to treat cardiovascular or endocrine/metabolic diseases may hint at the indications for which the pharma seeks to identify new targets and small molecule therapies through its partnership with the Sanford-Burnham Medical Research Institute.

Source: BCIQ: BioCentury Online Intelligence





Cardiovascular disease pipeline

Benicar/Olmec olmesartan

Angiotensin II type 1 receptor (AGTR1) antagonist

Marketed for hypertension

Pfizer Inc. (NYSE:PFE)

Azor/Sevikar olmesartan/amlodipine

Fixed-dose combination of olmesartan and amlodipine, a dihydropyridine calcium channel blocker

Marketed for hypertension

Not applicable

Benicar HCT olmesartan/hydrochlorothiazide

Fixed-dose combination of olmesartan and hydrochlorothiazide, a diuretic

Marketed for hypertension

Not applicable

Tribenzor/Sevikar HCT olmesartan/amlodipine/hydrochlorothiazide

Fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide

Marketed for hypertension

Not applicable

Effient prasugrel

Purinergic receptor P2Y G protein-coupled 12 (P2RY12; P2Y12) antagonist

Marketed for acute coronary syndrome; approved for ischemia/reperfusion injury

Eli Lilly and Co. (NYSE:LLY)

Lixiana edoxaban

Oral factor Xa inhibitor

Marketed for venous thromboembolism; in registration for fibrillation

Not applicable

Collategene beperminogene perplasmid (AMG0001; HGF gene therapy)

Plasmid encoding human hepatocyte growth factor/scatter factor (HGF/SF)

Phase III for ischemia/reperfusion injury

Vical Inc. (NASDAQ:VICL); AnGes MG Inc. (Tokyo:4563)

Phase III for peripheral vascular disease

Vical; AnGes MG; Mitsubishi Tanabe Pharma Corp. (Tokyo:4508)

CS-3150 (XL550)

Small molecule antagonist of the mineralocorticoid receptor

Phase II for hypertension

Exelixis Inc. (NASDAQ:EXEL)

Endocrine/metabolic disease pipeline

Sapropterin hydrochloride (Biopten Granules 10%)

Chemically synthesized form of natural tetrahydrobiopterin (THB; BH4)

Marketed for phenylketonuria

Not applicable

Kuvan sapropterin hydrochloride

Small molecule formulation of tetrahydrobiopterin

Marketed for phenylketonuria

BioMarin Pharmaceutical Inc. (NASDQ:BMRN); Merck KGaA (Xetra:MRK)

Tenelia teneligliptin

Dipeptidyl peptidase-4 (DPP-4; CD26) inhibitor

Marketed for type 2 diabetes

Mitsubishi Tanabe Pharma; Handok Inc. (KSE:002390)

Invokana canagliflozin

Sodium-glucose cotransporter 2 (SGLT2) inhibitor

Marketed for type 2 diabetes

Mitsubishi Tanabe Pharma; Johnson & Johnson (NYSE:JNJ)

Fastic/Starlix nateglinide

d-Phenylalanine amino acid derivative that blocks ATP-dependent potassium channel (KATP)

Marketed to prevent or treat type 2 diabetes

Novartis AG (NYSE:NVS; SIX:NOVN); Ajinomoto Co. Inc. (Tokyo:2802); Astellas Pharma Inc. (Tokyo:4503)

Cholestagel/Welchol colesevelam

Nonabsorbed bile acid sequestrant

Marketed for type 2 diabetes

Sanofi (Euronext:SAN; NYSE:SNY)

Marketed for hypercholesterolemia

Sanofi; Valeant Pharmaceuticals International Inc. (TXS:VRX; NYSE:VRX)

Benicar/Olmec olmesartan

AGTR1 antagonist

Phase III for diabetes

Not applicable


Solute carrier family 2 facilitated glucose transporter member 4 (SLC2A4; GLUT4) translocation enhancer

Phase I for diabetes

Not applicable


Cholesteryl ester transfer protein (CETP) inhibitor

Phase I for dyslipidemia

Not applicable


Glucokinase (GCK; GK) activator

Phase I for diabetes

Not applicable


G protein-coupled receptor 119 (GPR119) agonist

Phase I for diabetes

Not applicable